227 related articles for article (PubMed ID: 26431155)
1. MicroRNAs in Serum and Bile of Patients with Primary Sclerosing Cholangitis and/or Cholangiocarcinoma.
Voigtländer T; Gupta SK; Thum S; Fendrich J; Manns MP; Lankisch TO; Thum T
PLoS One; 2015; 10(10):e0139305. PubMed ID: 26431155
[TBL] [Abstract][Full Text] [Related]
2. Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.
Bernuzzi F; Marabita F; Lleo A; Carbone M; Mirolo M; Marzioni M; Alpini G; Alvaro D; Boberg KM; Locati M; Torzilli G; Rimassa L; Piscaglia F; He XS; Bowlus CL; Yang GX; Gershwin ME; Invernizzi P
Clin Exp Immunol; 2016 Jul; 185(1):61-71. PubMed ID: 26864161
[TBL] [Abstract][Full Text] [Related]
3. Pathological features of primary sclerosing cholangitis identified by bile proteomic analysis.
Rupp C; Bode KA; Leopold Y; Sauer P; Gotthardt DN
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1380-1389. PubMed ID: 28943450
[TBL] [Abstract][Full Text] [Related]
4. Calprotectin in bile: a disease severity marker in patients with primary sclerosing cholangitis.
Voigtländer T; Wlecke J; Negm AA; Lenzen H; Manns MP; Lankisch TO
J Clin Gastroenterol; 2014; 48(10):866-9. PubMed ID: 24440929
[TBL] [Abstract][Full Text] [Related]
5. CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis.
Björnsson E; Kilander A; Olsson R
Liver; 1999 Dec; 19(6):501-8. PubMed ID: 10661684
[TBL] [Abstract][Full Text] [Related]
6. Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis.
Banales JM; Iñarrairaegui M; Arbelaiz A; Milkiewicz P; Muntané J; Muñoz-Bellvis L; La Casta A; Gonzalez LM; Arretxe E; Alonso C; Martínez-Arranz I; Lapitz A; Santos-Laso A; Avila MA; Martínez-Chantar ML; Bujanda L; Marin JJG; Sangro B; Macias RIR
Hepatology; 2019 Aug; 70(2):547-562. PubMed ID: 30325540
[TBL] [Abstract][Full Text] [Related]
7. Analysis of U2 small nuclear RNA fragments in the bile differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders.
Baraniskin A; Nöpel-Dünnebacke S; Schumacher B; Gerges C; Bracht T; Sitek B; Meyer HE; Gerken G; Dechene A; Schlaak JF; Schroers R; Pox C; Schmiegel W; Hahn SA
Dig Dis Sci; 2014 Jul; 59(7):1436-41. PubMed ID: 24482036
[TBL] [Abstract][Full Text] [Related]
8. Volatile organic compounds in bile for early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis: a pilot study.
Navaneethan U; Parsi MA; Lourdusamy V; Bhatt A; Gutierrez NG; Grove D; Sanaka MR; Hammel JP; Stevens T; Vargo JJ; Dweik RA
Gastrointest Endosc; 2015 Apr; 81(4):943-9.e1. PubMed ID: 25500329
[TBL] [Abstract][Full Text] [Related]
9. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis.
Lankisch TO; Metzger J; Negm AA; Vosskuhl K; Schiffer E; Siwy J; Weismüller TJ; Schneider AS; Thedieck K; Baumeister R; Zürbig P; Weissinger EM; Manns MP; Mischak H; Wedemeyer J
Hepatology; 2011 Mar; 53(3):875-84. PubMed ID: 21374660
[TBL] [Abstract][Full Text] [Related]
10. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
Jendrek ST; Gotthardt D; Nitzsche T; Widmann L; Korf T; Michaels MA; Weiss KH; Liaskou E; Vesterhus M; Karlsen TH; Mindorf S; Schemmer P; Bär F; Teegen B; Schröder T; Ehlers M; Hammers CM; Komorowski L; Lehnert H; Fellermann K; Derer S; Hov JR; Sina C
Gut; 2017 Jan; 66(1):137-144. PubMed ID: 27406039
[TBL] [Abstract][Full Text] [Related]
11. Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis.
Vesterhus M; Holm A; Hov JR; Nygård S; Schrumpf E; Melum E; Thorbjørnsen LW; Paulsen V; Lundin K; Dale I; Gilja OH; Zweers SJLB; Vatn M; Schaap FG; Jansen PLM; Ueland T; Røsjø H; Moum B; Ponsioen CY; Boberg KM; Färkkilä M; Karlsen TH; Lund-Johansen F
J Hepatol; 2017 Jun; 66(6):1214-1222. PubMed ID: 28161472
[TBL] [Abstract][Full Text] [Related]
12. Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma.
Wu X; Xia M; Chen D; Wu F; Lv Z; Zhan Q; Jiao Y; Wang W; Chen G; An F
Tumour Biol; 2016 Nov; 37(11):15019-15029. PubMed ID: 27658773
[TBL] [Abstract][Full Text] [Related]
13. Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders.
Metzger J; Negm AA; Plentz RR; Weismüller TJ; Wedemeyer J; Karlsen TH; Dakna M; Mullen W; Mischak H; Manns MP; Lankisch TO
Gut; 2013 Jan; 62(1):122-30. PubMed ID: 22580416
[TBL] [Abstract][Full Text] [Related]
14. Differences in phosphatidylcholine and bile acids in bile from Egyptian and UK patients with and without cholangiocarcinoma.
Hashim Abdalla MS; Taylor-Robinson SD; Sharif AW; Williams HR; Crossey MM; Badra GA; Thillainayagam AV; Bansi DS; Thomas HC; Waked IA; Khan SA
HPB (Oxford); 2011 Jun; 13(6):385-90. PubMed ID: 21609370
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis.
Nichols JC; Gores GJ; LaRusso NF; Wiesner RH; Nagorney DM; Ritts RE
Mayo Clin Proc; 1993 Sep; 68(9):874-9. PubMed ID: 8396700
[TBL] [Abstract][Full Text] [Related]
16. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.
Hultcrantz R; Olsson R; Danielsson A; Järnerot G; Lööf L; Ryden BO; Wahren B; Broomé U
J Hepatol; 1999 Apr; 30(4):669-73. PubMed ID: 10207809
[TBL] [Abstract][Full Text] [Related]
17. Elevated Serum Bilirubin Level Correlates With the Development of Cholangiocarcinoma, Subsequent Liver Transplantation, and Death in Patients With Primary Sclerosing Cholangitis.
Haseeb A; Siddiqui A; Taylor LJ; Cox K; Adler DG
J Clin Gastroenterol; 2016; 50(5):431-5. PubMed ID: 26927495
[TBL] [Abstract][Full Text] [Related]
18. Angiopoietin-2 and biliary diseases: elevated serum, but not bile levels are associated with cholangiocarcinoma.
Voigtländer T; David S; Thamm K; Schlué J; Metzger J; Manns MP; Lankisch TO
PLoS One; 2014; 9(5):e97046. PubMed ID: 24823366
[TBL] [Abstract][Full Text] [Related]
19. Expression of p53 and PCNA in cholangiocarcinoma and primary sclerosing cholangitis.
Batheja N; Suriawinata A; Saxena R; Ionescu G; Schwartz M; Thung SN
Mod Pathol; 2000 Dec; 13(12):1265-8. PubMed ID: 11144921
[TBL] [Abstract][Full Text] [Related]
20. Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis.
Albiin N; Smith IC; Arnelo U; Lindberg B; Bergquist A; Dolenko B; Bryksina N; Bezabeh T
Acta Radiol; 2008 Oct; 49(8):855-62. PubMed ID: 18608012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
